<DOC>
	<DOCNO>NCT00795899</DOCNO>
	<brief_summary>The present clinical trial investigate safety efficacy sequential preoperative therapy Epirubicin/Cyclophosphamide combination Paclitaxel/Trastuzumab , follow postoperative Trastuzumab patient HER-2 overexpression primary breast cancer .</brief_summary>
	<brief_title>Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant ( TECHNO )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Primary carcinoma breast , confirm histologically core biopsy ( least 3 core biopsy sample ) 2 . Tumor lesion breast palpable imagistic size ≥ 2 cm inflammatory breast cancer 3 . Known HER2 status detect core biopsy . HER2 expression define DAKO HercepTest ( 3+ ) DAKO HercepTest ( 2+ ) FISH ( + ) ( fluorescenceinsituhybridisation ) . 4 . No distant metastatic disease , confirm chest xray , abdominal sonography bone scan . 5 . Female patient 6 . Age ≥ 18 ≤ 65 year 7 . ECOG &lt; 2/WHO 01 8 . Laboratory requirement GOT Bilirubin &lt; 1.5x UNL Leukocytes &gt; = 3 G/l Neutrophile &gt; 1 G/l Thrombocytes &gt; 100 G/l Creatinine ( Serum ) &lt; 2.0 mg/dl . 9 . Normal cardiac function , confirm cardiologist 10 . No active hepatitis 11 . Written inform consent study procedures 12 . Patients must available compliant treatment followup 1 . Multicentricity various quadrant ( contact study office ) 2 . CNSmetastases 3 . Secondary malignancy , exclude basalioma skin carcinoma situ cervix receive curative therapy 4 . Patients relevant hemodynamic cardial diseases 5 . Patients leave ventricular ejection fraction ( LVEF ) normal limit institution , confirm echocardiography MUGAScan . 6 . Uncontrolled , severe comorbidities 7 . Patients severe respiratory disease severe dyspnea / need supportive oxygen 8 . Previous antiHER2therapy 9 . Patients receive immunosuppressant therapy 10 . Known allergy medication contain cremophor 11 . Hb &lt; 10 g/dL , Neutrophile &lt; 1.5 x109/L , Thrombocytes &lt; 100 x109/L . 12 . TotalSerumBilirubin &gt; 1.5 x ULN ( upper limit normal ) ( except patient confirm documented GilbertLereboulletsyndrome ) , ALT AST &gt; 2.5 x ULN ( &gt; 5 x ULN liver metastasis ) , Alkaline Phosphatase &gt; 2.5 x ULN ( &gt; 4 x ULN liver bone metastasis ) , Serumcreatinine &gt; 2 x ULN 13 . Pregnancy , nursing ( negative pregnancy test must document , safe anticontraceptive measure pre postoperative treatment must implement ) 14 . Lack sign informed consent inform patient 15 . Lack willingness keep disclose personal medical data part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Safety efficacy experimental treatment</keyword>
</DOC>